ClinicalTrials.gg
RecruitingNCT04644016Updated Mar 13, 2026

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

A Phase 2 interventional study of Clofarabine and Fludarabine in AML, ALL and MDS, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing clofarabine in Lymphoma, Non-Hodgkin — 3 open to participants now, 3 under way, none of them phase 3. Clofarabine · Lymphoma, Non-Hodgkin.

Planned enrollment
7th of 16
31 · median 24
Started
2020
the only one that year
Phase 2
9 of 16
3 open now
Registered
15th of 16
by date
Lead sponsor
3 of 16
Memorial Sloan Kettering Cancer Center

Among the 16 studies testing clofarabine in Lymphoma, Non-Hodgkin, this one is the 7th largest by planned enrollment, is the only one that started in 2020, is one of 9 in phase 2, and was the 15th registered.

Lymphoma, Non-Hodgkin

2,289 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 16 studies testing clofarabine in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About clofarabine

Clofarabine: first FDA approval 2004 (CLOLAR), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 241 Lymphoma, Non-Hodgkin studies recruiting now, 141 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing clofarabine in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.

03

Conditions studied

  • AML
  • ALL
  • MDS
  • MPD Withou Myelofibrosis
  • NHL or HL
  • Inherited Metabolic Disorders
  • Hemoglobinopathies
  • Bone Marrow Failure
  • HLH

Keywords

  • Acute myelogenous leukemia
  • AML
  • Myelodysplasia
  • MDS
  • Myeloproliferative Disorder
  • Therapy-Related AML and MDS
  • Therapy-Related Acute Myeloid Leukemia
  • T-AML
  • High-risk cytogenetics
  • Cord Blood Transplantation
  • 20-480
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participant Inclusion Criteria:

Age and Donor Status:

Patients with age ≤ 21 years at time of consent with no available and suitably matched related or unrelated donor in the required time period.

Diagnoses :

I. Acute myelogenous leukemia (AML) :

  • Complete first remission (CR1) at high risk for relapse such as any of the following:

    • Known prior diagnosis of myelodysplasia (MDS) or myeloproliferative disorder (MPS).
    • Therapy-related AML (t-AML).
    • White cell count at presentation > 100,000.
    • Presence of extramedullary leukemia at diagnosis.
    • Any unfavorable subtype by FAB or WHO classification.
    • High-risk cytogenetics (e.g. those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) or high-risk molecular abnormalities.
    • Requirement for 2 or more inductions to achieve CR1.
    • Presence of Minimal Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods after induction.
    • Any patient with newly diagnosed AML with intermediate risk cytogenetics who elects allograft with curative intent over consolidation chemotherapy.
    • Any patient unable to tolerate consolidation chemotherapy as would have been deemed appropriate by the treating physician.
    • Other high-risk features not defined above.
  • Complete second remission (CR2).
  • Primary or relapsed AML with less than 10% blasts by bone marrow morphology. Patients with cytogenetic, flow cytometric, or molecular abnormalities in ≤ 10% of cells are eligible.

II. Acute lymphoblastic leukemia (ALL):

  • Complete first remission (CR1) at high risk for relapse such as any of the following:

    • White cell count at presentation > 30,000 for B-cell lineage and > 100,000 for T-cell lineage.
    • Presence of any high-risk cytogenetic abnormalities such as t (9;22), t (1;19), t (4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality.
    • Failure to achieve complete remission (CR) after four weeks of induction therapy.
    • Persistence or recurrence of MRD on therapy.
    • Any patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician.
    • Other high-risk features not defined above.
  • Complete second remission (CR2).
  • Primary refractory or relapsed ALL with MRD disease after antibody therapy (e.g., blinatumomab, inotuzumab, other) and/or CAR-T cell therapy.

III. Other acute leukemias:

Leukemias of ambiguous lineage or of other types (e.g. blastic plasmacytoid dendritic cell neoplasm) with less than 5% blasts by BM morphology. Patients with persistent/relapsed disease with cytogenetic, flow cytometric or molecular aberrations in ≤ 5% of cells are eligible.

IV. Myelodysplastic Syndrome (MDS) / Myeloproliferative Disorders (MPD) other than myelofibrosis:

  • International prognostic scoring system (IPSS) risk score of INT-2 or high risk at the time of diagnosis.
  • Any IPSS risk category if life-threatening cytopenia(s) exists.
  • Any IPSS risk category with karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia.
  • MDS/ myeloproliferative disorder overlap syndromes without myelofibrosis.
  • MDS/ MPD patients must have less than 10% bone marrow myeloblasts and ≥ 0.2 (growth factor supported if necessary) at transplant work-up.

V. Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) at high-risk of relapse or progression if not in remission:

  • Eligible patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histology) in CR.
  • Eligible patients with indolent B cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with stable disease/ CR/ PR with no single lesion equal to or more than 5 cm.
  • Eligible patients with HL will be those without progression of disease (POD) after salvage chemotherapy with no single lesion ≥ 5 cm.

VI. Inherited Metabolic Disorders [also see EBMT Handbook for discussion on patient eligibility for transplant; in general, patients are considered early in the disease course, before they develop neurologic symptoms (46)]:

  • Hurler Syndrome
  • Hunter (MPS 2 - early disease)
  • Sly syndrome (MPSVIII)
  • α-Mannosidosis
  • X- ALD
  • Osteopetrosis
  • Metachromatic Leukodystrophy
  • Globoid (GLD)

VII. Non-Malignant disorders (other) [also see EBMT Handbook for criteria for transplant (46)]

  • Hemoglobinopathies
  • Bone Marrow Failure syndromes
  • Immunodeficiencies, including HLH

Organ Function and Performance Status Criteria:

  • or Lansky score ≥ 70% (see Appendix)
  • ≤ 1.5 mg/dL (unless benign congenital hyperbilirubinemia).
  • ≤ 3 x .
  • Pulmonary function (spirometry and corrected DLCO) ≥ 50% predicted (corrected for ) .
  • ≥ 50%.
  • Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) less than or equal to 7.
  • Renal: serum creatinine ≤ 1.5x normal for age. If serum creatinine is outside the normal range, then > 50 mL/min/1.73m2 (calculated or estimated) or (mL/min/1.72m2) >30% of predicted normal for age.

Normal GFR in Children and Young Adults (Age) : Mean GFR +- SD (mL/min/1.73 m2)

1 week: 40.6 + / - 14.8 2-8 weeks: 65.8 + / - 24.8 >8 weeks: 95.7 + / - 21.7 2-12 years: 133.0 + / - 27.0 13-21 years (males): 140.0 + / - 30.0 13-21 years (females: 126.0 + / - 22.0

GFR, glomerular filtration rate; SD, standard deviation greater than 2 years old: Normal GFR is 100 mL/ min. Infants: GFR must be corrected for body surf ace area.

For metabolic diseases: disease status to be evaluated according to EBMT Handbook [45].

Graft Criteria

CB units will be selected according to the current MSKCC unit selection algorithm. High resolution 8 allele HLA typing and recipient HLA antibody profile will be performed. Cord unit selection will occur based on HLA-match, total nucleated cell (TNC) and CD34+ cell dose adjusted per patient body weight. The cord bank of origin will also be considered. Donor specific HLA antibodies, if present, will also be taken into consideration and may influence the selection of the graft. CB graft will consist of one or two CB units (CBU) based on MSKCC selection algorithm.

  • Each CB unit must be at least 3/8 HLA-matched to the patient considering high-resolution 8-allele HLA typing.
  • For malignant diseases follow MSKCC CBU selection algorithm
  • For non-malignant diseases, CBU will be required to have > 5 x 107 TNC/kg; high HLA allele level match is preferable

Participant Exclusion Criteria:

  • Inadequate performance status/ organ function.
  • Advanced metabolic disease (EBMT handbook).
  • Active CNS leukemic involvement.
  • Indolent NHL or Hodgkin lymphoma with progression of disease after most recent salvage chemotherapy.
  • Diagnosis of myelofibrosis or other with moderate-severe bone marrow fibrosis.
  • Autologous stem cell transplant within the preceding 6 months.
  • Any prior allogeneic stem cell transplant.
  • Active and uncontrolled infection (bacterial/fungal/viral) at time of transplantation.
  • infection.
  • Seropositivity for HTLV-1.
  • Pregnancy or breast feeding.
  • Patient or guardian unable to give or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Participants with malignant hematologic disorders

    Patients with malignant disorders receive clofarabine intravenously (IV) over 2 hours, fludarabine phosphate (fludarabine) IV over 30 minutes, and busulfan IV over 3 hours on days -5 to -2. Beginning on day -3, patients receive tacrolimus IV or orally (PO) and mycophenolate mofetil IV over at least 2 hours in the absence of unacceptable toxicity. Patients may begin to taper tacrolimus at approximately 3 months post-transplant and mycophenolate mofetil at approximately 60 days post-transplant in the absence of ongoing graft versus host disease (GVHD) requiring systemic immune suppression. TRANSPLANT: Patients undergo cord blood transplantation (CBT) on day 0.\*\*Subgroup will get rATG (day -12 to -10) POST-TRANSPLANT: Beginning on day 7, patients receive filgrastim subcutaneously (SC) or IV over 15-30 minutes until absolute neutrophil count (ANC) recovery. Additionally, patients undergo blood sample collection, computed tomography (CT) and positron emission tomography (PET) on study.

    Drug: Clofarabine · Drug: Fludarabine · Drug: Busulfan · Drug: Cyclosporine-A · Drug: Mycophenolate Mofetil · Biological: Cord Blood Graft

  • Experimental
    Participants with non-malignant hematologic disorders

    Patients with non-malignant disorders receive rituximab IV on day -12 and rabbit anti-thymocyte globulin (rATG) over 12 hours on day -12 to -9. Patients then receive clofarabine IV over 2 hours, fludarabine IV over 30 minutes, and busulfan IV over 3 hours on days -5 to -2. Beginning on day -3, patients receive tacrolimus IV or PO and mycophenolate mofetil IV over at least 2 hours. Patients may begin to taper tacrolimus at approximately 6 months post-transplant and mycophenolate mofetil at approximately 60 days post-transplant in the absence of ongoing GVHD requiring systemic immune suppression. TRANSPLANT: Patients undergo CBT on day 0. POST-TRANSPLANT: Beginning on day 7, patients receive filgrastim SC or IV over 15-30 minutes until ANC recovery. Patients also receive rituximab IV on day 30. Additionally, patients undergo blood sample collection, CT and PET on study.

    Drug: Clofarabine · Drug: Fludarabine · Drug: Busulfan · Drug: Cyclosporine-A · Drug: Mycophenolate Mofetil · Biological: Cord Blood Graft

Interventions

  • Clofarabine

    Also known as: Clolar

  • Fludarabine

    Also known as: Fludara

  • Busulfan per PK

    Also known as: Busulfex

  • DrugCyclosporineStudies of CyclosporineCyclosporine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

    Also known as: CSA

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    GVHD prophylaxis will consist of cyclosporine-A (CSA) and mycophenolate mofetil (MMF) starting day -3.

    Also known as: MMF

  • BiologicalCord Blood Graft

    The CB graft will be infused on day 0 per standard practice

    Also known as: CB graft

06

What researchers measure

Primary outcomes

  1. Treatment related mortality at 1 year after myeloablative cord transplant

    The primary objective of this study is to assess treatment related mortality (TRM) at 1 year after myeloablative cord transplant.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Maria Cancio, MD · Contact212-639-2446
    • E. · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2026, 73 months after the start.

Of 170 non-industry phase 2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 111. This study's planned 73 months is close to that.

Counting every sponsor, half of 220 studies reached it within 65 months; a quarter within 41 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2020
First posted
Nov 25, 2020
StartActual
Nov 20, 2020
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 20, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04644016
Responsible party
Sponsor
First posted
Nov 25, 2020
Start date
Nov 20, 2020
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 20, 2026 (estimated)
Last update
Mar 13, 2026

Study contacts

Maria I Cancio, MD
Contact
canciom@mskcc.org
212-639-2446
Jaap Jan Boelens, MD, PhD
Contact
boelensj@mskcc.org
212-639-3643
Maria Cancio, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clofarabine · Fludarabine · Busulfan · Cyclosporine · Mycophenolic Acid

Start the discussion